Join our community of smart investors

Oxford Nanopore downgrades guidance

The company needs to diversify its revenue streams and grow its customer base as legacy business dries up
March 6, 2024
  • Growth in operating expenses
  • Cash burn

Genomic sequencing group Oxford Nanopore Technologies (ONT) spent much of last year in an in-between space: revenue from two of its major contracts was dwindling as it made greater investments in securing new business. Unsurprisingly, its losses widened as a result.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in